For millions of people living with obesity, the class of weight-loss medications known as GLP-1 agonists have been game-changers (think Wegovy and Zepbound). Studies show that people on these medications can lose more weight than they can with just lifestyle changes alone. But for one group of Americans — people on Medicare — at least some of these drugs have been off-limits because Medicare is not allowed to cover medications prescribed for the sole purpose of weight loss. With ample evidence that obesity itself increases numerous health risks and new indications that these drugs lower risks of heart disease and…